Selective β1-adrenoceptor antagonist (Ki values are 47, 2960 and 10100 nM for β1, β2 and β3 adrenoceptors respectively). Inhibits spontaneous endothelin-1 production in vitro and displays antihypertensive and antianginal activity in vivo.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 342.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.92 mL||14.6 mL||29.21 mL|
|5 mM||0.58 mL||2.92 mL||5.84 mL|
|10 mM||0.29 mL||1.46 mL||2.92 mL|
|50 mM||0.06 mL||0.29 mL||0.58 mL|
References are publications that support the products' biological activity.
Garlichs et al (1999) Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur.J.Clin.Invest. 29 12 PMID: 10092983
Dasbiswas et al (2008) S-metoprolol: The 2008 Clinical Review. J.Indian.Med.Assoc. 106 259 PMID: 18828349
If you know of a relevant reference for Metoprolol tartrate, please let us know.
View Related Products by Product Action
Keywords: Metoprolol tartrate, supplier, Selective, α1-adrenoceptor, beta1-adrenoceptor, b1-adrenoceptor, antagonists, b1-adrenergic, β1-Adrenergic, beta1-Adrenergic, Receptors, Adrenergic, Beta-1, Receptors, Adrenergic, Beta-1, Receptors, Tocris Bioscience
Citations for Metoprolol tartrate
Citations are publications that use Tocris products.
Currently there are no citations for Metoprolol tartrate. Do you know of a great paper that uses Metoprolol tartrate from Tocris? If so please let us know.
Metoprolol tartrate Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.